ABOUT THE MEETING

The ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Program Committee for the Annual Meeting chaired by Drs. Mark Rapaport and Tiffany Farchione including representatives from the ASCP Community, FDA, EMA, NIMH, NIDA, NIAAA, and the academia members, lead the direction of the meeting. The Review Subcommittee, under the leadership of Drs. Manish Jha and Carlos Blanco, are responsible for the review of all program submissions. To ensure the meeting includes the needs of our loyal pharmaceutical industry members, we are excited to announce the launch of the ASCP Industry Advisory Council led by Drs. Ross Baker and Julie Adams.

The ASCP Annual Meeting brings together over 900 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator Awardees.  ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented. For more information about the history and purpose of the ASCP Annual Meeting please click here.

In recent years, the ASCP Annual Meeting focus has been expanded to address a number of timely issues relevant to clinical research in psychiatry, including the translation of research into practice, the importance of regulatory issues, and pharmacogenetics and other means to personalizing interventions.
 

Submissions are OPEN for the 2025 ASCP Annual Meeting.

Listed below are the submissions accepted for the ASCP Annual Meetings.

OPEN FOR SUBMISSIONS

• Poster Presentation – Poster board presentation in a general session.
  Deadline: January 29, 2025
• Donald Klein Lifetime Achievement Award - This award is given to a recipient who has made an outstanding contribution to the Clinical Psychopharmacology field. Any scientist, clinician or upstanding ASCP member may nominate an individual for this award by submitting the following to the Awards Committee. The candidate should be a leader in the field above the age of 70 or have achieved an academic “emeritus” rank. Although overall impact on the field of clinical psychopharmacology is the primary consideration for meriting the Donald Klein Lifetime Achievement Award, the nominee’s involvement in the organization will be taken into consideration during the selection process.
• Deadline: January 29, 2025

Paul Wender Best Paper In The Journal of Clinical Psychiatry Award - Presented by the ASCP to to a recipient who has been published in the past year (January 2023 to present date) for The Journal of Clinical Psychiatry.

• Deadline: January 29, 2025
• Henry Nasrallah Award for Excellence in Clinical Psychopharmacology Education- This award will be given annually to recognize outstanding contributions in clinical psychopharmacology education and teaching. 2025 will mark its inaugural year. ASCP membership is not a requirement for receiving this distinguished award 
• Deadline: January 29, 2025
• Pharmaceutical Pipeline Presentations – A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest.
  Deadline: February 20, 2025
• • Late-Breaking Posters– Late-breaking science included in the poster session.
    Deadline: March 28, 2025

CLOSED FOR SUBMISSIONS

Panel Sessions* – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length.
Deadline: December 6, 2024

Workshop Sessions* – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length.
Deadline: December 6, 2024

PAST ASCP ANNUAL MEETINGS